Insider Trading Alert - CRM, CYS And MU Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 2, 2014, 147 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $416.76 to $333,500,000.00.

Highlighted Stocks Traded by Insiders:

Salesforce.com (CRM) - FREE Research Report

Conway Craig, who is Director at Salesforce.com, sold 1,600 shares at $52.26 on May 2, 2014. Following this transaction, the Director owned 12,656 shares meaning that the stake was reduced by 11.22% with the 1,600-share transaction.

The shares most recently traded at $52.08, down $0.18, or 0.34% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 1,024
  • 12-Week # shares sold: 6,782
  • 24-Week # shares sold: 91,582

The average volume for Salesforce.com has been 6.7 million shares per day over the past 30 days. Salesforce.com has a market cap of $31.0 billion and is part of the technology sector and computer software & services industry. Shares are down 8.03% year-to-date as of the close of trading on Wednesday.

salesforce.com, inc. provides enterprise cloud computing solutions to various businesses and industries worldwide. Currently, there are 26 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings rates Salesforce.com as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and generally higher debt management risk. Get the full Salesforce.com Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CYS Investments (CYS) - FREE Research Report

Grant Kevin E, who is Chairman, CEO, CIO, President at CYS Investments, sold 44,154 shares at $8.56 on May 2, 2014. Following this transaction, the Chairman, CEO, CIO, President owned 561,781 shares meaning that the stake was reduced by 7.29% with the 44,154-share transaction.

The shares most recently traded at $8.61, up $0.05, or 0.58% since the insider transaction. Historical insider transactions for CYS Investments go as follows:

  • 4-Week # shares sold: 170,332
  • 12-Week # shares bought: 34,248
  • 12-Week # shares sold: 170,332
  • 24-Week # shares bought: 34,248
  • 24-Week # shares sold: 170,332

The average volume for CYS Investments has been 2.9 million shares per day over the past 30 days. CYS Investments has a market cap of $1.4 billion and is part of the financial sector and real estate industry. Shares are up 14.04% year-to-date as of the close of trading on Wednesday.

CYS Investments, Inc., a specialty finance company, makes leveraged investments in whole-pool residential mortgage pass-through securities where the principal and interest payments are guaranteed. The stock currently has a dividend yield of 14.5%. Currently, there are 4 analysts who rate CYS Investments a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYS - FREE

TheStreet Quant Ratings rates CYS Investments as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full CYS Investments Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Micron Technology (MU) - FREE Research Report

Bailey Robert L, who is Director at Micron Technology, sold 2,000 shares at $26.40 on May 2, 2014. Following this transaction, the Director owned 129,751 shares meaning that the stake was reduced by 1.52% with the 2,000-share transaction.

The shares most recently traded at $26.25, down $0.15, or 0.56% since the insider transaction. Historical insider transactions for Micron Technology go as follows:

  • 4-Week # shares sold: 280,000
  • 12-Week # shares sold: 317,000
  • 24-Week # shares sold: 840,492

The average volume for Micron Technology has been 32.5 million shares per day over the past 30 days. Micron Technology has a market cap of $26.9 billion and is part of the technology sector and electronics industry. Shares are up 15.4% year-to-date as of the close of trading on Wednesday.

Micron Technology, Inc., together with its subsidiaries, manufactures and markets semiconductor solutions worldwide. The company has a P/E ratio of 14.4. Currently, there are 11 analysts who rate Micron Technology a buy, 3 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MU - FREE

TheStreet Quant Ratings rates Micron Technology as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Micron Technology Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing